What is Zacks Research’s Forecast for Sanofi Q2 Earnings?

Sanofi (NASDAQ:SNY) – Investment analysts at Zacks Research lifted their Q2 2027 earnings per share (EPS) estimates for shares of Sanofi in a note issued to investors on Monday, November 10th. Zacks Research analyst Team now expects that the company will post earnings of $1.20 per share for the quarter, up from their previous forecast of $1.18. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q3 2027 earnings at $1.46 EPS and FY2027 earnings at $5.08 EPS.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business had revenue of $14.53 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter last year, the business posted $2.25 EPS. The business’s quarterly revenue was down 7.5% compared to the same quarter last year.

A number of other equities research analysts also recently commented on the stock. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $56.00 to $58.00 in a report on Monday, September 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, November 5th. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $62.67.

Sanofi Stock Up 1.3%

NASDAQ:SNY traded up $0.66 during mid-day trading on Wednesday, hitting $52.35. The stock had a trading volume of 40,627 shares, compared to its average volume of 2,704,010. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The stock has a 50-day simple moving average of $48.70 and a two-hundred day simple moving average of $49.43. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $128.54 billion, a PE ratio of 12.24, a PEG ratio of 1.38 and a beta of 0.49.

Institutional Trading of Sanofi

Several hedge funds have recently modified their holdings of the business. AlphaCore Capital LLC raised its position in Sanofi by 441.9% in the third quarter. AlphaCore Capital LLC now owns 15,234 shares of the company’s stock worth $719,000 after acquiring an additional 12,423 shares in the last quarter. TD Asset Management Inc increased its holdings in Sanofi by 20.9% in the third quarter. TD Asset Management Inc now owns 337,539 shares of the company’s stock valued at $15,932,000 after buying an additional 58,252 shares in the last quarter. Parr Mcknight Wealth Management Group LLC lifted its position in shares of Sanofi by 1.8% during the 3rd quarter. Parr Mcknight Wealth Management Group LLC now owns 31,268 shares of the company’s stock valued at $1,476,000 after acquiring an additional 538 shares during the period. Legacy Financial Advisors Inc. purchased a new stake in shares of Sanofi during the 3rd quarter worth approximately $290,000. Finally, Vestmark Advisory Solutions Inc. boosted its stake in shares of Sanofi by 16.1% during the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 56,465 shares of the company’s stock worth $2,665,000 after acquiring an additional 7,829 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.